Comprehensive Safety Exposure-Response Analysis to Support Ritlecitinib Dose Selection
May 2025
in “
CPT Pharmacometrics & Systems Pharmacology
”
Research cited in this study
5 / 5 resultsresearch Efficacy and Safety of Deuruxolitinib, an Oral Selective Janus Kinase Inhibitor, in Adults with Alopecia Areata: Results from the Phase 3 Randomized, Controlled Trial (THRIVE-AA1)
research Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
research Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial
research Two Phase 3 Trials of Baricitinib for Alopecia Areata
Baricitinib was effective in treating alopecia areata in two major trials.
research Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents
Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
Related Research
1 / 1 results
research Efficacy and Safety of Microneedling Radiofrequency in Patterned Hair Loss
Microneedling radiofrequency significantly improves hair growth with minimal side effects.